Intervacc AB (FRA:2E9) Marketable Securities: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2E9 Intervacc AB FRA:2E9
63 GF Score
Price €0.10
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is Intervacc AB Marketable Securities?

Intervacc AB FRA:2E9 -1.14% 63 Marketable Securities is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Intervacc AB's Marketable Securities for the quarter that ended in Mar. 2026 was €0.00 Mil.

Intervacc AB  (FRA:2E9) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Intervacc AB Marketable Securities Related Terms

Intervacc AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Intervacc AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intervacc AB Marketable Securities Chart

Intervacc AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Intervacc AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2E9
63GF Score
Intervacc AB FRA:2E9
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intervacc AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Intervacc AB (FRA:2E9) has a Marketable Securities of €0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Intervacc AB and its competitors.
Is Intervacc AB's Marketable Securities too high?
Intervacc AB's current Marketable Securities is €0.00 Mil. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Marketable Securities compare to VRTX and REGN?
Intervacc AB's Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Intervacc AB and its competitors. Intervacc AB's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Marketable Securities of €0.00 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.10 — trading 19.8% above its estimated fair value. The current Marketable Securities is €0.00 Mil. Intervacc AB's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Marketable Securities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intervacc AB (FRA:2E9) Overvalued in 2026?

Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued. The current stock price of €0.10 is trading 19.8% above its estimated GF Value™ of €0.08.

Key valuation signals for FRA:2E9:

  • Marketable Securities: €0.00 Mil
  • GF Value™: €0.08 vs. price of €0.10 (19.8% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intervacc AB Business Description

Other Exchanges IVACC:Sweden
Address Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score

Get the complete analysis for FRA:2E9

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.08
GF Value